In April 2014, after the drugmaker Mylan hiked prices on more than seven of its drugs, Teva Pharmaceutical Industries, the world’s largest generic drugmaker and one of Mylan’s biggest rivals, allegedly wanted to increase its prices, too.
Just four days later, Teva employees were sharing detailed breakdowns of those Mylan price increases internally, according to a new lawsuit being brought by 44 states against Teva, Mylan, and 18 other generic drugmakers.
Business Insider obtained an unredacted copy of the complaint, which recounts alleged communications between employees of rival companies by way of email, Facebook message, and spreadsheets. The goal was to coordinate on drug pricing and deals with customers, the complaint alleges.
The lawsuit is the second to be brought as part of an investigation by the states into generic drugs, which are typically thought of as low-cost treatment options. The complaints have brought new scrutiny to the medications’ prices and to the business practices of generic drug companies.
SUBSCRIBE TO READ OUR STORY: Inside the secret messages that allegedly show how big drug companies plotted to increase the price of your medicines
- We spoke with a key Merck executive about the strategy for its top cancer drug, a $7 billion powerhouse that could soon bring in more than $20 billion
- CVS Health just gave a 174-slide presentation on the future of the company. Here are 8 crucial slides that show how it plans to transform the way Americans get healthcare.
- CVS Health just revealed plans to dramatically expand its strategy to upend how Americans get healthcare as it takes on Amazon